US regulatory status: approved.
pharma · Head and Neck Neoplasms · Rheumatoid Arthritis
Chinese University of
Chinese University of Hong Kong
Chinese University of drug portfolio — 55 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 42
- Drugs
- 55
- Patents
- 0
Chinese University of pipeline
Portfolio lens on 55 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Chinese University of drug portfolio — 55 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Chinese University of in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in Chinese University of's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
Development asset linked to Chinese University of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-t)
Antineoplastic and immunomodulating agents (L03)Antineoplastic and immunomodulating agents (L03) compound in Chinese University of's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
baricitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
US regulatory status: approved. Molecular target: ATP synthase.
- Target
- ATP synthase
- Mechanism
- ATP synthase inhibitor
-
US regulatory status: approved. Mechanism: Membrane staining aid in ophthalmic surgery.
- Mechanism
- Membrane staining aid in ophthalmic surgery
-
Development asset linked to Chinese University of in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Chinese University of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Chinese University of's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Chinese University of's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Chinese University of in public FDA and regional records. Molecular target: Envelope glycoprotein E.
- Target
- Envelope glycoprotein E
- Mechanism
- Envelope glycoprotein E vaccine antigen
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
fezolinetant
Genito-urinary system and sex hormones (G02)US regulatory status: approved. Molecular target: Neuromedin-K receptor.
- Target
- Neuromedin-K receptor
- Mechanism
- Neurokinin 3 receptor antagonist
-
finerenone
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor antagonist
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
US regulatory status: approved.
-
imatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Chinese University of's portfolio. Mechanism: Tyrosine-protein kinase ABL inhibitor.
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
interferon alfa-2a
Antineoplastic and immunomodulating agents (L03)Antineoplastic and immunomodulating agents (L03) compound in Chinese University of's portfolio. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
meningococcal group a, c, w-135 and y conjugate vaccine
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Chinese University of's portfolio. Mechanism: Immunostimulant.
- Mechanism
- Immunostimulant
-
Development asset linked to Chinese University of in public FDA and regional records. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.
- Target
- Polyunsaturated fatty acid 5-lipoxygenase
- Mechanism
- Arachidonate 5-lipoxygenase inhibitor
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Chinese University of in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Chinese University of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
- Target
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
tacrolimus
Dermatologicals (D11)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
telbivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
telmisartan
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records.
-
Development asset linked to Chinese University of in public FDA and regional records. Molecular target: Succinate-semialdehyde dehydrogenase, mitochondrial.
- Target
- Succinate-semialdehyde dehydrogenase, mitochondrial
- Mechanism
- Succinate semialdehyde dehydrogenase inhibitor
-
Development asset linked to Chinese University of in public FDA and regional records.